FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Revises Janssen Covid Vaccine Fact Sheets

[ Price : $8.95]

FDA says fact sheets for the Janssen Covid-19 vaccine have been updated with a Contraindication for the vaccine in individuals wit...

Device Definition Draft Guidance

[ Price : $8.95]

FDA issues a draft guidance on the redesignation of the definition of device in the Federal Food, Drug, and Cosmetic Act and the a...

Abdominal Pain Nerve Stimulator is Class 2

[ Price : $8.95]

Federal Register notice: FDA classifies the nonimplanted nerve stimulator for functional abdominal pain relief into Class 2 (speci...

Endoscopic Transhepatic Venous Needle is Class 2

[ Price : $8.95]

Federal Register notice: FDA classifies the endoscopic transhepatic venous access needle into Class 2 (special controls).

FDA Proposes PMAs for Spinal Spheres

[ Price : $8.95]

Federal Register notice: FDA proposes to require PMAs for spinal spheres for use in intervertebral fusion procedures.

Biden Bill Will Hurt Generic Drugs: Analysis

[ Price : $8.95]

A health and science policy analyst for Citizens Against Government Waste says the Build Back Better act proposed by President Bid...

Comments on ICH Q13 Continuous Manufacturing Guidance

[ Price : $8.95]

Three stakeholders submit comments and questions on a draft International Council on Harmonization guidance on continuous manufact...

AbbVie Gains Rinvoq Psoriatic Arthritis Approval

[ Price : $8.95]

FDA approves AbbVies JAK inhibitor Rinvoq (upadacitinib; 15 mg, once daily) for treating adults with active psoriatic arthritis wh...

FDA Approves BMS Orencia for Graft Versus Host Disease

[ Price : $8.95]

FDA approves a new indication for Bristol-Myers Squibbs Orencia to prevent acute graft versus host disease in combination with imm...

FDA Approves Xeljanz for Ankylosing Spondylitis

[ Price : $8.95]

FDA approves a Pfizer supplemental NDA for its JAK inhibitor Xeljanz /Xeljanz XR (tofacitinib) for treating adults with active ank...